Micro Assays for HemATology Malignancies Antibody Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

blood sampling: Additional blood sampling as part of routine care

Study summary

Hematological malignancy is a disease of the blood. In some cases, this pathology requires therapeutic management, which is not necessarily the case for you. Nevertheless, to improve the management of patients who need it, we are conducting research to assess the state of your immune system. Indeed, the role of the immune system is not limited to controlling infections, but is also important in controlling the proliferation of cancer cells, in hematology as in other types of cancer. Your immune system can play a spontaneous anti-tumor control role, but some so-called "immunotherapy" treatments aim to destroy cancer cells by stimulating the immune system, restoring its capabilities, and directing the immune response against tumor cells. For this immunotherapy treatment to be effective, since it uses your own immune cells (in most cases), these cells must be in a state to respond and be able to destroy the tumor. It is this ability to activate immune cells that is tested in this research protocol, using a simple test that could in future be used in routine clinical practice. But to understand why these immune cells don't work, we will also have to carry out genetic tests to analyze the various molecules that could interfere with the immune response, and try to inhibit the molecules that prevent the immune response.

Eligibility

Primary outcome measure(s)

• Percentages of immune effectors — At the enrollement in the study
  Percentages of immune effectors responding to stimulation, assessed in patients with hematological malignancies

Trial sites (1)

More Assistance Publique Hopitaux De Marseille trials in France

Other trials for the same condition